PITTSBURGH, April 25 /PRNewswire-FirstCall/ -- Mylan Laboratories Inc. (NYSE: MYL) today announced that Mylan Pharmaceuticals Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Cilostazol Tablets, 50mg and 100 mg. Cilostazol Tablets are the AB-rated generic equivalent of Otsuka Pharmaceutical's Pletal^® Tablets, which had U.S. sales of approximately $84 million for the 12-month period ending December 31, 2005, according to IMS Health.

This product will be shipped immediately.

Mylan Laboratories Inc. is a leading pharmaceutical company with three principal subsidiaries, Mylan Pharmaceuticals Inc., Mylan Technologies Inc. and UDL Laboratories, Inc., that develop, license, manufacture, market and distribute an extensive line of generic and proprietary products.

For more information about Mylan, visit www.mylan.com.

SOURCE Mylan Laboratories Inc.
04/25/2006
CONTACT: Media, Patrick Fitzgerald, +1-724-514-1800, or Investors, Kris
King, +1-724-514-1800, both of Mylan Laboratories Inc.
Web site: http://www.mylan.com
(MYL)